14 results
8-K
EX-99.1
SPRY
ARS Pharmaceuticals Inc
6 Dec 22
Regulation FD Disclosure
5:07pm
Health Co., Former CEO of Allergan (acq. $63B), Actavis, Forest Labs, and Bausch + Lomb (acq. $8.7B) Michael Kelly Former President, US Operations
8-K
EX-99.1
SPRY
ARS Pharmaceuticals Inc
16 May 23
Regulation FD Disclosure
4:31pm
of experience Brent Saunders Chairman at The Beauty Health Co., Former CEO of Allergan (acq. $63B), Actavis, Forest Labs, and Bausch + Lomb (acq. $8.7B
8-K
EX-99.2
SPRY
ARS Pharmaceuticals Inc
21 Jul 22
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
5:01pm
at The Beauty Health Co., Former CEO of Allergan (acq. $63B), Actavis, Forest Labs, and Bausch + Lomb (acq. $8.7B) Michael Kelly Former President, US
8-K
SPRY
ARS Pharmaceuticals Inc
8 Nov 22
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
4:51pm
Officer of Forest Laboratories Inc. (formerly NYSE:FRX), a pharmaceutical company focused on therapeutic areas of the central nervous and cardiovascular
DEF 14A
50vc27xw9 2zv79mwy
22 Apr 21
Definitive proxy
4:01pm
DEFA14A
jgamp9i6465 kk
21 Jul 22
Additional proxy soliciting materials
5:05pm
DRS
epry4r
2 Oct 20
Draft registration statement
12:00am
S-1
e50ayt8oy1caje5nj
10 Nov 20
IPO registration
4:46pm
424B4
ig4wvss2kk3 hvir
4 Dec 20
Prospectus supplement with pricing info
4:04pm
S-1/A
vqvkpnc rd
30 Nov 20
IPO registration (amended)
6:06am
- Prev
- 1
- Next